The Gene Team
Funding from Retina UK has allowed to team to explore the viability of gene therapy as a treatment for RP and related conditions, and build a pipeline of clinical trials.
Search
Search results
Aavantgarde Bio Ush1B study at Moorfields
Aavantgarde Bio Ush1B study at Moorfields
Opus Genetics – the next BEST thing!
The latest research news from Retina UK.
Charities demand increase in benefits
Charities representing blind and partially sighted people are urging the UK Government to increase benefits in line with inflation rather than wages, when a decision is made at the end of the month.
AAVantgarde Completes Enrolment in Phase 1/2 Clinical Trial for Usher Syndrome Type B
The latest research news piece from Retina UK.
Research update – ProQR
In February 2022, ProQR announced a disappointing outcome for their phase 2/3 trial of sepofarsen for Leber congenital amaurosis type 10 (LCA10).
Encouraging results from ProQR USH2A clinical trial
Biotechnology company ProQR has announced encouraging results from its phase 1/2 clinical trial of an innovative treatment for sight loss caused by faults in a specific section of the USH2A gene.
e-Newsletter October 2025
Our monthly e-Newsletter featuring the latest updates from Retina UK.
e-Newsletter February 2024
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.
Look Forward – Spring 2023 – Issue 179
The Spring 2023 edition of the Retina UK newsletter, Look Forward, which includes articles about our upcoming events, research updates and more.